Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986453 in Relapsed/Refractory Multiple Myeloma
NCT06153251Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Primary completion
- May 2030
- Modality
- CAR-T Cells
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of BMS-986453 in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with treatment-emergent adverse events at 4 years, Number of participants with serious adverse events at 4 years and 3 more. Started Jan 2024; status: recruiting.
02
Drugs
BMS-986453
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06153251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153251.